Founded by Ishani Malhotra in 2018 , Carcinotech is a MedTech company with expertise in manufacturing 3D-printed living tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Carcinotech’s advanced models provide a platform for rapid, ethical, sustainable, and accurate drug screening, pre-clinical and personalised medicine testing.
The company’s vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to each individual suffering from cancer, to better their chance of treatment and survival.
Working with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry leaders, the goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Access to Carcinotech’s robotic and automated manufacturing allows for accelerated production, with models offering high-throughput capabilities.
Gabriel has provided funding to accelerate Carcinotech’s proof of concept, which allowed them to validate their technology and collect robust data to get clients onboard. We have also supported with business advice and mentoring alongside supporting the company’s commercial and business development activities.
